中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (10): 899-904.doi: 10.19401/j.cnki.1007-3639.2021.10.004

• 论著 • 上一篇    下一篇

胃癌中RNA解旋酶DDX19A的表达及临床意义

张美智子,郭佳雯,周丽丽,程 玉   

  1. 承德医学院基础医学院,河北 承德 067000
  • 出版日期:2021-10-30 发布日期:2021-11-09
  • 通信作者: 程 玉 E-mail: 369383126@qq.com
  • 基金资助:
    河北省科学技术厅2021年大中学生科技创新能力培育专项项目(2021H080605);河北省重点学科建设项目[冀教高(2013)4号病理学与病理生理学];承德医学院2020年基本科研业务费课题(KY2020011)。

Expression of RNA helicase DDX19A and its clinical significance in gastric cancer

ZHANG Meizhizi, GUO Jiawen, ZHOU Lili, CHENG Yu   

  1. Basic Medical College of Chengde Medical College, Chengde 067000, Hebei Province, China
  • Published:2021-10-30 Online:2021-11-09
  • Contact: CHENG Yu E-mail: 369383126@qq.com

摘要: 背景与目的:RNA解旋酶DDX19A(DEAD-box helicases 19A)是DDX蛋白超家族的成员之一,主要参与RNA的转运过程。该家族的许多成员参与肿瘤的发生及发展过程,然而关于DDX19A在胃癌中的作用,目前尚未见报道。结合生物信息学分析,探讨胃癌组织中DDX19A的表达情况及临床意义。方法:采用UALCAN数据库,转录水平分析胃癌及癌旁胃组织中DDX19A的表达差异,进一步分析其在胃癌中的表达及与临床分期的关系;采用Kaplan-Meier Plotter数据库分析DDX19A表达水平与胃癌患者总生存期(overall survival,OS)及无病生存期(disease-free survival,DFS)的相关性。采用蛋白质印迹法(Western blot)检测16对冻存的新鲜胃癌组织及配对癌旁胃黏膜中DDX19A蛋白的表达。收集2011—2015年承德医学院附属医院病理科存档的胃癌石蜡包埋标本109例、癌旁胃黏膜标本30例,所有患者临床病理学资料完整。免疫组织化学S-P四步法检测109例胃癌及30例癌旁胃黏膜中DDX19A蛋白的表达,分析其高表达与胃癌临床病理学特征及预后的关系。结果:UALCAN及Kaplan-Meier Plotter数据库检索结果显示,DDX19A mRNA在胃癌组织中的表达明显高于癌旁胃组织(P<0.01),其高表达与胃癌临床分期及患者不良预后正相关(P<0.05)。Western blot结果显示,胃癌组织中DDX19A蛋白显著高表达(P<0.01)。免疫组织化学结果显示,胃癌组织中的DDX19A阳性表达率为68.8%(75/109),显著高于其在癌旁胃黏膜中的表达(33.3%,10/30),差异有统计学意义(P<0.01)。DDX19A高表达与胃癌分化程度、浸润深度、TNM分期密切相关(P<0.05),而与患者性别、年龄、肿瘤大小、淋巴结转移无关(P>0.05)。69例随访资料完整的病例中,DDX19A高表达患者的OS明显短于低表达患者(P<0.05)。结论:DDX19A在胃癌组织中明显高表达,并且其高表达与胃癌临床分期、侵袭性及患者不良预后相关。DDX19A有望成为与胃癌预后相关的潜在生物标志物及治疗的新靶点。

关键词: 胃肿瘤, DDX19A, 预后, UALCAN, Kaplan-Meier Plotter

Abstract: Background and purpose: RNA helicase DEAD-box helicase 19A (DDX19A), a member of the DDX protein superfamily, is mainly involved in the RNA transport process. Many members of this family are involved in the genesis and progression of tumors, however, the role of DDX19A in gastric cancer has not been reported. Combined with bioinformatics analysis, the expression of DDX19A in gastric cancer tissues and its clinical significance were investigated. Methods: The UALCAN database was used to analyze the expression difference of DDX19A in gastric cancer tissues and adjacent gastric tissues at the transcriptional level, and the relationship between its expression in gastric cancer and clinical stage was further analyzed. Kaplan-Meier Plotter database was used to analyze the correlation between DDX19A expression level and overall survival (OS) and disease-free survival (DFS) of gastric cancer patients. Western blot assay was used to detect the expression of DDX19A protein in 16 pairs of frozen fresh gastric cancer tissues and adjacent gastric mucosa. A total of 109 paraffin specimens of gastric cancer and 30 paracancerous gastric mucosa specimens were collected from Department of Pathology, Affiliated Hospital of Chengde Medical College from 2011 to 2015, and clinicopathological data of all patients were complete. Immunohistochemical S-P four-step method was used to detect the expression of DDX19A protein in 109 cases of gastric cancer and 30 cases of adjacent gastric mucosa. The relationship between the overexpression of DDX19A protein and the clinicopathological characteristics and prognosis of gastric cancer was statistically analyzed. Results: UALCAN and Kaplan-Meier Plotter database search results showed that DDX19A mRNA expression was significantly higher in gastric cancer tissues than in adjacent gastric tissues (P<0.01), and its high expression was positively correlated with clinical stage and poor prognosis of gastric cancer patients (P<0.05). Western blot results showed that DDX19A protein was significantly overexpressed in gastric cancer tissues (P<0.01). Immunohistochemical experiments showed that the positive expression rate of DDX19A in gastric cancer tissues was 68.8% (75/109), which was significantly higher than that in paracancerous gastric mucosa (33.3%, 10/30) (P<0.01). The high expression of DDX19A was closely related to the differentiation degree, infiltration depth and TNM stage of gastric cancer (P<0.05), but not to gender, age, tumor size or lymph node metastasis (P>0.05). In 69 cases with complete follow-up data, the OS of patients with high DDX19A expression was significantly lower compared with those with low DDX19A expression (P<0.05). Conclusion: DDX19A is highly expressed in gastric cancer tissues, and is associated with clinical staging, invasiveness and poor prognosis of patients. It is expected to be a potential biomarker and a new therapeutic target related to the prognosis of gastric cancer.

Key words: Gastric cancer, DDX19A, Prognosis, UALCAN, Kaplan-Meier Plotter